Riyadh Daily
By Adam Feuerstein Nov. 5, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard , a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.
You can reach Adam on Signal at stataf.54. The commercial debut of Revolution Medicines’ pancreatic cancer drug Rasonque was eye-popping and jaw-dropping: $198 million in sales in just five weeks following the U.S. approval of the groundbreaking pan-RAS inhibitor. More than 5,000 patients have already been treated with the drug, the company said Wednesday evening.
“The U.S. launch of Rasonque is off to a strong start,” said Revolution Chief Commercial Officer Anthony Mancini, on the company’s earnings call — perhaps the understatement of the year in commercial biotech. Rasonque’s sales performance was nearly double even the most bullish investor estimates heading into the company’s third-quarter earnings announcement. It might be too early to call Rasonque the best cancer drug launch in history, but it’s certainly close, and investors are now re-evaluating their forecasts for what lies ahead.
STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account?
Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe
Source: STAT
